Table 1

Baseline characterisics for all patients and divided according to eGFR with the CKD-EPI equation

AllSubgroup with atrial fibrillation
N=40 736N=20 976
Age (years), median (IQR)77 (67–84)79 (71–85)
Diabetes25.2 %23.4%
Ischaemic heart disease48.7%42.4%
Duration of heart failure <6 months51.4%46.4%
Inpatient registration66.6%71.1%
Atrial fibrillation (history of and/or on ECG)51.5%100%
ECG with atrial fibrillation at visit/hospitalisation39.1%75.8%
Device therapy
Echocardiography findings
 LVEF ≥50%21.80%25.6%
 LVEF 40%–49%20.50%21.9%
 LVEF 30%–39%27.60%26.3%
 LVEF <30%30.10%26.3%
Treatment year
Renal function
 Creatinine (mmol/L), median (IQR)97 (79–125)100 (81–128)
 CKD-EPI eGFR (mL/min/1.73 m2), median (IQR)59 (42–77)56 (41–73)
 MDRD eGFR (mL/min/1.73 m2), median (IQR)59 (43–75)57 (42–72)
 Cockcoft-Gault eGFR (mL/min), median (IQR)57 (39–82)53 (37–75)
 BSA, median (IQR) (missing)1.90 (1.75–2.06) (21 141)1.91 (1.75–2.06) (11 036)
Current medication
 ACE inhibitor/angiotensin receptor blocker80.9%79.3%
  • *BSA estimated with the DuBois and DuBois formula,17 which is based on weight (kg) and height (cm) (BSA = (weight0.425 x height0.725) x 0.007184).

  • BSA, body surface area; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; ICD, International Classification of Diseases; LVEF, left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease Study; NYHA, New York Heart Association.